According to Cerevel Therapeutics's latest financial reports the company has a price-to-book ratio of 13.2.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2024-12-31 | N/A | -100% |
2023-12-31 | 11.4 | 20.18% |
2022-12-31 | 9.46 | 14.68% |
2021-12-31 | 8.25 | 50.47% |
2020-12-31 | 5.48 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Archer Daniels Midland (ADM)
ADM | 1.26 | -90.41% | ๐บ๐ธ USA |
Campbell Soup CPB | 3.37 | -74.40% | ๐บ๐ธ USA |
Dow DOW | 2.13 | -83.81% | ๐บ๐ธ USA |
Dupont De Nemours DD | 1.42 | -89.19% | ๐บ๐ธ USA |